Bryleos Information

Early clinical stage therapeutics company developing BRY101, a patent-pending oral composition of NAD+ engineered to increase intracellular NAD+. BRY101 is a potential high-value medicine to treat challenging and costly diseases of aging where the common denominator is a disruption of NAD homeostatis at a cellular level. In 2022, the Company completed its double-blind, placebo-controlled Feasibility Study at the Institute of Systems Biology. The study of 60 healthy adults demonstrated a 52% increase in intracellular NAD levels against placebo within just 5 days Bryleos: More Life While Living